Genexine. has filed a patent for a pharmaceutical formulation containing a modified IL-7 protein. The formulation includes a modified IL-7 fusion protein, a basal buffer, a sugar, and a surfactant. This formulation does not form aggregates and has protective effects on proteins under stress conditions. It is intended for the treatment of patients. GlobalData’s report on Genexine gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Genexine, Peptide pharmacophores was a key innovation area identified from patents. Genexine's grant share as of September 2023 was 25%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical formulation comprising modified il-7 fusion protein
A recently filed patent (Publication Number: US20230279069A1) describes a pharmaceutical formulation that includes an interleukin-7 (IL-7) protein conjugated to a Fc region of an immunoglobulin (IL-7 fusion protein). The formulation also contains a basal buffer with a concentration of 10 to 50 mM, a sugar with a concentration of 2.5 to 5 w/v%, and a surfactant with a concentration of 0.05 to 6 w/v%. The IL-7 fusion protein may include an oligopeptide consisting of 1 to 10 amino acid residues, which can be selected from a specific group of sequences listed in the patent. The oligopeptide is bound to the N-terminal of the IL-7 protein. The IL-7 protein itself can have different amino acid residue sequences, including amino acid residues 26-178 of SEQ ID NO: 1, amino acid residues 26-155 of SEQ ID NO: 2, amino acid residues 26-155 of SEQ ID NO: 3, amino acid residues 26-178 of SEQ ID NO: 4, amino acid residues 26-177 of SEQ ID NO: 5, or amino acid residues 26-177 of SEQ ID NO: 6.
The pharmaceutical formulation may also include a basal buffer of histidine-acetate or sodium citrate, a sugar selected from sucrose, trehalose, dextrose, or a mixture thereof, and a surfactant selected from polysorbate, polyoxyethylene alkyl ether, polyoxyethylene stearate, alkyl sulfates, polyvinyl pyridone, poloxamer, or a mixture thereof. Additionally, the formulation may contain an amino acid selected from arginine, glutamate, glycine, histidine, or a mixture thereof, with a concentration ranging from 40 to 60 mM, and a sugar alcohol of 1 to 2 w/v%. The pH of the formulation is 5.0, and it is in liquid form.
The patent also describes methods of increasing the stability of the IL-7 fusion protein by admixing it in the aforementioned formulation. Another method described is reducing aggregation in the pharmaceutical formulation by admixing the IL-7 fusion protein in a basal buffer. Furthermore, the patent claims a method of treating a disease or disorder in a subject by administering the pharmaceutical formulation.
Overall, this patent presents a pharmaceutical formulation containing an IL-7 fusion protein, which can be used for increasing stability and reducing aggregation. The formulation includes specific concentrations of basal buffer, sugar, and surfactant, along with optional amino acids and sugar alcohols. The patent also covers methods of using the formulation for treating diseases or disorders in subjects.
To know more about GlobalData’s detailed insights on Genexine, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
